DE60024243T2 - Verbesserte krebsbehandlung mit temozolomid - Google Patents

Verbesserte krebsbehandlung mit temozolomid Download PDF

Info

Publication number
DE60024243T2
DE60024243T2 DE60024243T DE60024243T DE60024243T2 DE 60024243 T2 DE60024243 T2 DE 60024243T2 DE 60024243 T DE60024243 T DE 60024243T DE 60024243 T DE60024243 T DE 60024243T DE 60024243 T2 DE60024243 T2 DE 60024243T2
Authority
DE
Germany
Prior art keywords
temozolomide
use according
day
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60024243T
Other languages
German (de)
English (en)
Other versions
DE60024243D1 (de
Inventor
H. Mohamed RAGAB
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE60024243D1 publication Critical patent/DE60024243D1/de
Application granted granted Critical
Publication of DE60024243T2 publication Critical patent/DE60024243T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60024243T 1999-03-30 2000-03-27 Verbesserte krebsbehandlung mit temozolomid Expired - Lifetime DE60024243T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28134899A 1999-03-30 1999-03-30
US281348 1999-03-30
PCT/US2000/008079 WO2000057867A2 (en) 1999-03-30 2000-03-27 Improved cancer treatment with temozolomide

Publications (2)

Publication Number Publication Date
DE60024243D1 DE60024243D1 (de) 2005-12-29
DE60024243T2 true DE60024243T2 (de) 2006-08-17

Family

ID=23076905

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60024243T Expired - Lifetime DE60024243T2 (de) 1999-03-30 2000-03-27 Verbesserte krebsbehandlung mit temozolomid

Country Status (18)

Country Link
EP (1) EP1165071B1 (https=)
JP (2) JP2002540148A (https=)
CN (2) CN1345240A (https=)
AR (1) AR023185A1 (https=)
AT (1) ATE310515T1 (https=)
AU (1) AU780892B2 (https=)
BR (1) BR0009380A (https=)
CA (1) CA2368614C (https=)
DE (1) DE60024243T2 (https=)
DK (1) DK1165071T3 (https=)
ES (1) ES2251987T3 (https=)
HK (1) HK1044111B (https=)
HU (1) HUP0200805A3 (https=)
NO (1) NO330651B1 (https=)
NZ (1) NZ536302A (https=)
TW (1) TWI276434B (https=)
WO (1) WO2000057867A2 (https=)
ZA (1) ZA200107736B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100366249C (zh) * 2002-09-29 2008-02-06 天津帝士力投资控股集团有限公司 一种替莫唑胺控释给药系统
CN1742723A (zh) * 2004-09-02 2006-03-08 天津倍方科技发展有限公司 含有替莫唑胺－8－羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途
CN1299772C (zh) * 2004-10-14 2007-02-14 孔庆忠 一种抗癌药物组合物
NZ554831A (en) * 2004-11-09 2009-10-30 Schering Corp Improved dosing regimen of temozolomide for treating cancer based on the patientÆs MGMT level
ME02121B (me) * 2006-01-17 2014-06-30 Abbvie Ireland Unlimited Co Kombinovana terapija sa parp inhibitorima
SG10201500028RA (en) * 2006-04-05 2015-02-27 Opko Health Inc Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
AR061618A1 (es) * 2006-06-26 2008-09-10 Schering Corp Formas de dosificacion unitaria de temozolomida
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
JP5199263B2 (ja) * 2006-09-29 2013-05-15 シプラ・リミテッド テモゾロミドと類似体を調製するための改善された方法
US20140005160A1 (en) * 2010-12-01 2014-01-02 Hooshmand SHESHBARADARAN Method for Treating Refractory Cancer
CN102526038B (zh) * 2011-01-12 2013-09-11 北京人福军威医药技术开发有限公司 替莫唑胺的脑靶向药物组合物及其应用
CN107397735B (zh) * 2017-07-28 2020-07-10 东曜药业有限公司 一种替莫唑胺药物组合物及其制备方法和应用
CN117338750A (zh) * 2023-11-24 2024-01-05 郑州德迈药业有限公司 一种替莫唑胺制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2233544A1 (en) * 1995-10-04 1997-04-10 Schering Corporation Combination temozolomide and alpha-ifn for the treatment of advanced cancer
CA2184545A1 (en) * 1996-07-31 1998-02-01 Pascale Reidenberg Cancer treatment with temozolomide
CA2184546A1 (en) * 1996-07-31 1998-02-01 Margaret H. Dugan Method for treating pediatric high grade astrocytoma including brain stem glioma

Also Published As

Publication number Publication date
HK1044111A1 (en) 2002-10-11
AR023185A1 (es) 2002-09-04
CN1345240A (zh) 2002-04-17
DE60024243D1 (de) 2005-12-29
BR0009380A (pt) 2001-12-26
NO20014725L (no) 2001-11-13
HUP0200805A2 (hu) 2002-07-29
CA2368614C (en) 2008-07-22
NO20014725D0 (no) 2001-09-28
ES2251987T3 (es) 2006-05-16
NO330651B1 (no) 2011-05-30
HK1044111B (en) 2006-02-24
ATE310515T1 (de) 2005-12-15
WO2000057867A2 (en) 2000-10-05
AU3924400A (en) 2000-10-16
NZ536302A (en) 2006-05-26
ZA200107736B (en) 2003-02-26
EP1165071B1 (en) 2005-11-23
WO2000057867A3 (en) 2001-04-19
JP2002540148A (ja) 2002-11-26
EP1165071A2 (en) 2002-01-02
AU780892B2 (en) 2005-04-21
JP2007169297A (ja) 2007-07-05
TWI276434B (en) 2007-03-21
CA2368614A1 (en) 2000-10-05
DK1165071T3 (da) 2006-02-20
CN102160864A (zh) 2011-08-24
HUP0200805A3 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
DE60024243T2 (de) Verbesserte krebsbehandlung mit temozolomid
DE69931766T2 (de) Antitumorale mittel
DE60016602T2 (de) Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel
DE69904922T2 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
JPS6075454A (ja) 鎮痛用新規化合物および組成物
DE69129331T2 (de) Verwendung von inosittriphosphat zur zubereitung von medikamenten
DE69323759T2 (de) Verwendung von toremifene für die behandlung von sle
EP0185210B1 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
DE68916958T2 (de) Topisch angebrachter goldorganokomplex.
US5824346A (en) Combination therapy for advanced cancer
DE60212710T2 (de) Pharmazeutische zubereitungen enthaltend epothilone und deren verwendung bei der behandlung von karzinoid
EP1545553B1 (de) Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten
DE60126225T2 (de) Zusammensetzung zur Behandlung von Tumoren oder Krebs, welche Fluorouracil und ein Methylol Übertragungsmittel enthält
US4569929A (en) Cytidyl diphosphocholine-drug composition
DE60120917T2 (de) Kombinationspräparat zur krebstherapie
Goh Erythema multiforme-like and purpuric eruption due to contact allergy to proflavine.
DE69408394T2 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
EP0858341B1 (en) Combination therapy for advanced cancer comprising temozolomide and cisplatin
DE69625373T2 (de) Kombination von temozolomide und alpha-interferon zur behandlung von fortgeschrittenem krebs
EP1420789A1 (de) Verwendung von wirkstoffen mit mu-opioid-rezeptor agonistischer wirkung und opioid-rezeptor antagonistischer wirkung als kombinationsarzneimittel zur krebsbehandlung
Borsi et al. Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin
US5942247A (en) Method for treating pediatric high grade astrocytoma including brain stem glioma
EP2026789A2 (de) Neue, an der tumorphysiologie orientierte formulierung eines zytostatikums, insbesondere von cis-platin
DE60316775T2 (de) Kombinationspräparat aus epothilone derivate und imidazotetrazinone
DE69007439T2 (de) Mittel gegen Tumore.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition